

## The typical reactivity of C5aR specific mAbs





Figure 1

## Certain mAbs to C5aR inhibit ligand binding

### [125I] C5a Ligand Binding Assay



**Figure 2**

3/15

## MAb 7F3 inhibition of ligand binding- dose response

### Inhibition of radiolabelled C5a




Figure 3

4/15

### Complete inhibition of C5aR transfected chemotaxis by select antibodies





Figure 4

5/15

## Complete inhibition of L1.2 C5aR transfectant chemotaxis



**Figure 5**

6/15




Figure 6

7/15




Figure 7

8/15




Figure 8

9/15




Figure 9a

10/15




Figure 9b

11/15




Figure 10

12/15

**Anti-C5aR MAbs variable light chain DNA sequences**

	10	20	30	40	50
7F3 Vk	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCAGTCTGGAAA				
6c12 Vk	GATGTTGTGATGACCCAATTCACCTCTCCCTGCCTGTCAGTCTGGAGA				
12d4 Vk	GATGTTGTGATGACCCAATCCACCTCTCCCTGCCTGTCAGTCTGGAGA				
	*****				
	60	70	80	90	100
7F3 Vk	TCAAGCCTCCATCTCTGCGAGATCTAGTCAGAGCCTTGTACACAGTAATG				
6c12 Vk	TCAAAACCTCCATCTCTGCGAGATCTAGTCAGAGCCTTATACACAGTAATG				
12d4 Vk	TCAAGCCTCCATCTCTGTAGATCTAGTCAGAGCCTTGTACACAGTAGTG				
	*****				
	110	120	130	140	150
7F3 Vk	GAAACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAG				
6c12 Vk	GAAACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAG				
12d4 Vk	GAAACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAG				
	*****				
	160	170	180	190	200
7F3 Vk	CTCCTGATCTACAAAGTTCCAACCGATTCTGGGTCCCAGACAGGTT				
6c12 Vk	CTCCTGATCTACAAAGTTCCAACCGATTCTGGGTCCCAGACAGGTT				
12d4 Vk	CTCCTGATCTACAAAGTCTCCAACCGATTCTGGGTCCCAGACAGGTT				
	*****				
	210	220	230	240	250
7F3 Vk	CAGTGGCAGTGGATCAGGGACAGATTTCTCACTCAAGATCAGCAGAGTGG				
6c12 Vk	CAGTGGCAGTGGATCAGGGACAGATTTCACTCAAGATCAGCAGAGTGG				
12d4 Vk	CAGTGGCAGTGGATCAGGGACACATTCACTCAAGATCAGCAGAGTGG				
	*****				
	260	270	280	290	300
7F3 Vk	AGGCTGAGGATCTGGAGTTATTCTGCTCTCAAAGTACACTTGTTCCTG				
6c12 Vk	AGGCTGAGGATATGGAGTTATTCTGCTCTCAAAGTACACATGTTCCTG				
12d4 Vk	AGGCTGAGGATCTGGGAATTATTCTGCTCTCAAAGTACACTTGTTCCTG				
	*****				
	310	320	330		
7F3 Vk	CTCACGTTGGTGGCTGGACCAAGCTGGAACTGAAA				
6c12 Vk	CCGACGTTGGTGGAGGGCACCAAGCTGGAAATCAAA				
12d4 Vk	CCGACGTTGGTGGAGGGCACCAAGCTGGAAATCAAA				
	* *****				

**Figure 11**

13/15

**Anti-C5aR MAbs variable heavy chain DNA sequences**

	10	20	30	40	50
7F3 Vh	CAGGTTCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGCCTC				
6c12 Vh	CAGGTTCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGCCTC				
12d4 Vh	CAGGTGCAGCTGAAGGAGTCAGGACCTGGCTGGCGCCCTCACAGAG				
	*****	*****	*****	*****	***
	60	70	80	90	100
7F3 Vh	AGTGAAGATTTCTGCAAGGCTTCTGGCTACGCATTAGTAACCTGGAA				
6c12 Vh	AGTGAAGATTTCTGCAAGGCTTCTGGCTACGCATTAGTAGTCCTGGAA				
12d4 Vh	CCTGTCCATCACATGCACTGTCTGGGTTCTCATTAACCAGCTATGGTG				
	**	**	*****	* ****	* * * *
	110	120	130	140	150
7F3 Vh	TGAACTGGGTGAAGCAGAGGCCTGGAAAGGGTCTTGAGTGGATTGGACGG				
6c12 Vh	TGAACTGGGTGAAGCAGAGGCCTGGAAAGGGTCTTGAGTGGATTGGACGG				
12d4 Vh	TAGACTGGGTCGCCAGTCTCCAGGAAAGGGTCTGGAGTGGCTGGGAGTA				
	*****	***	**	*****	***** * ***
	160	170	180	190	200
7F3 Vh	ATTATCTGGAGATGGAGATACTAAGTACAATGGAAAGTTCAAGGGCAA				
6c12 Vh	ATTGATGCTGGAGATGGAGATACTAAATACAATGGAAAGTTCAAGGGCAA				
12d4 Vh	ATATG---GGGTGTTGGAAGCACAATTATAATTCAAGCTCTCAAATCCAG				
	**	**	*****	* * * * *	***** **
	210	220	230	240	250
7F3 Vh	GGCCACACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAACTCA				
6c12 Vh	GGCCACACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAACTCA				
12d4 Vh	ACTGAGCATCAGCAAGGACAACCTCCAAGAGCCAAGTTTCTTAAAAATGA				
	*	*	*****	***	* * * * * * * *
	260	270	280	290	300
7F3 Vh	GCAGCCTGACATCTGAGGACTCTGCGGTCTATTCTGTGCAAGATTCTA				
6c12 Vh	GCAGCCTGACATCTGAGGACTCTGCGGTCTACTCTGTGCAAGCCTCTC				
12d4 Vh	ACAGTCTGCAAACGTGATGACGCAAGCCATGTACTACTGTGCCAGCCACT--				
	***	***	*****	* * * * *	***** **
	310	320	330	340	350
7F3 Vh	CTTATTAGTACGGTAACAGCCGTTGACTACTGGGGCCAAGGCACCACTCT				
6c12 Vh	ATTACTACGGTAGTGGGAGCTATGGACTACTGGGGTCAAGGAACCTCAGT				
12d4 Vh	ATGGTTACGGACGGCTGGGT-TTGCTTACTGGGGCCAAGGGACTCTGGT				
	*	**	*	* * * * *	***** * *
	360				
7F3 Vh	CACAGTCTCCTCA				
6c12 Vh	CACCGTCTCCTCA				
12d4 Vh	CACTGTCTGTCA				
	***	*****	*		

**Figure 12**

14/15

**Anti-C5aR MAb variable light chain protein sequences**

		FR1	CDR1			FR2
		10	20	30	40	50
7F3 Vk		DVVMTQSPSLPVSLGNQASISC		RSSQSLVHSNGNTYLN		WYLQKPGQSPK
6c12 Vk		DVVMTQIPLSLPVSLGDQTSISC		RSSQSLIHSNGNTYLN		WYLQKPGQSPK
12d4 Vk		DVVMTQTPSLSLPVSLGDQASISC		RSSQSLVHSSGNTYLN		WYLQKPGQSPK
		*****	*****	*****	*****	*****
		CDR2	FR3			CDR3
		60	70	80	90	100
7F3 Vk	LLIY	KVSNRFS	GVPDRFSGSGSGTDFSLKIS	RVEAEDLGVYFC		SQSTLVP
6c12 Vk	LLIY	KVSNRFS	GVPDRFSGSGSGTDFTLKIS	RVEAEDMGVYFC		SQSTHVP
12d4 Vk	LLIY	KVSNRFS	GVPDRFSGSGSGTHFTLKIS	RVEAEDLGIYFC		SQSTLVP
		*****	*****	*****	*****	*****
		FR4				
		110				
7F3 Vk	LT	FGAGTKLELK				
6c12 Vk	PT	FGGGTKLEIK				
12d4 Vk	PT	FGGGTKLEIK				
	*	***	*****	.*		

**Figure 13**

15/15

**Anti-C5aR MAb variable heavy chain protein sequences**

	FR1			CDR1			FR2			
	10	20	30	NSWMN	WVKQRPKGLEWIG	R	40	50		
7F3 Vh	QVOLQSGPELVKPGASVKISCKASGYAFS			RSWMN	WVKQRPKGLEWIG	R				
6c12 Vh	QVOLQSGPEVVKPGASVKISCKASGYAFS			SYGVD	WVRQSPGKGLEWLG	V				
12d4 Vh	QVQLKESGPGLVAPSQSLSITCTVSGFSLT	*****.****	.* * * . * . * . * . * .	.	***.* *****.**					
	CDR2			FR3			CDR3			
	60	70	80	KATLTADKSSTAYMQLSSLTSEDSAVYFCAR		90	100			
7F3 Vh	IYPGDGDTKYNGKFKG	KATLTADKSSTAYMQLSSLTSEDSAVYFCAR					FL			
6c12 Vh	IDAGDGDTKYNGKFKG	KATLTADKSSTAYMQLSSLTSEDSAVYFCAS					LL			
12d4 Vh	IW-GVGSTNYNSALKS	RLSISKDNSKSQVFLKMNSLQTDDAAMYYCAS					HY			
	* * * * *	.	... * * *	....	** ..*.*..**					
	CDR3			FR4						
	110	120		WGQGTTLT	VSS					
7F3 Vh	LISVTAVDY	WGQGTTLT		VSS						
6c12 Vh	ITTVVGAMDY	WGQGTSVT		VSS						
12d4 Vh	GYDGLG-FAY	WGQGTLVT		VSV						
	*	*****	.	***						

**Figure 14**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**